| Scott P Bronnimann, MD | |
|
2055 W Hospital Dr, Ste 205, Tucson, AZ 85704-7892 | |
| (520) 575-6944 | |
| (520) 575-1115 |
| Full Name | Scott P Bronnimann |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 45 Years |
| Location | 2055 W Hospital Dr, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467417402 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 14545 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yuma Regional Medical Center | Yuma, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yuma Regional Medical Center | 2062314826 | 288 |
News Archive
IDC, today announced that it has signed an agreement with Merge Healthcare Inc. to provide their ProPlanner software package to IDC's growing number of Orthopaedic digital radiography (DR) customers.
Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.
New research into HIV/AIDS therapy has found that starting treatment with drugs for the AIDS virus may be better sooner than later as victims are more than 70% less likely to die when they started taking cocktails of HIV drugs earlier than currently recommended.
A Mount Sinai-led research team has discovered a new kind of stem cell that can become either a liver cell or a cell that lines liver blood vessels, according to a study published today in the journal Stem Cell Reports. The existence of such a cell type contradicts current theory on how organs arise from cell layers in the embryo, and may hold clues to origins of, and future treatment for, liver cancer.
Medications remain the mainstay of epilepsy treatment, and to date there are no FDA-approved devices that provide an accurate means of detection for generalized tonic-clonic seizures, or convulsions, during activities of daily living. Two new studies presented at the American Epilepsy Society's 67th Annual Meeting in Washington D.C. provide data that warrants the development of non-invasive devices with the capability to signal the onset of an epileptic seizure and could be crucial to optimal patient dosing.
› Verified 3 days ago
| Entity Name | Yuma Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194706655 PECOS PAC ID: 2062314826 Enrollment ID: O20040122000526 |
News Archive
IDC, today announced that it has signed an agreement with Merge Healthcare Inc. to provide their ProPlanner software package to IDC's growing number of Orthopaedic digital radiography (DR) customers.
Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.
New research into HIV/AIDS therapy has found that starting treatment with drugs for the AIDS virus may be better sooner than later as victims are more than 70% less likely to die when they started taking cocktails of HIV drugs earlier than currently recommended.
A Mount Sinai-led research team has discovered a new kind of stem cell that can become either a liver cell or a cell that lines liver blood vessels, according to a study published today in the journal Stem Cell Reports. The existence of such a cell type contradicts current theory on how organs arise from cell layers in the embryo, and may hold clues to origins of, and future treatment for, liver cancer.
Medications remain the mainstay of epilepsy treatment, and to date there are no FDA-approved devices that provide an accurate means of detection for generalized tonic-clonic seizures, or convulsions, during activities of daily living. Two new studies presented at the American Epilepsy Society's 67th Annual Meeting in Washington D.C. provide data that warrants the development of non-invasive devices with the capability to signal the onset of an epileptic seizure and could be crucial to optimal patient dosing.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott P Bronnimann, MD 2055 W Hospital Dr, Ste 205, Tucson, AZ 85704-7892 Ph: (520) 575-6944 | Scott P Bronnimann, MD 2055 W Hospital Dr, Ste 205, Tucson, AZ 85704-7892 Ph: (520) 575-6944 |
News Archive
IDC, today announced that it has signed an agreement with Merge Healthcare Inc. to provide their ProPlanner software package to IDC's growing number of Orthopaedic digital radiography (DR) customers.
Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.
New research into HIV/AIDS therapy has found that starting treatment with drugs for the AIDS virus may be better sooner than later as victims are more than 70% less likely to die when they started taking cocktails of HIV drugs earlier than currently recommended.
A Mount Sinai-led research team has discovered a new kind of stem cell that can become either a liver cell or a cell that lines liver blood vessels, according to a study published today in the journal Stem Cell Reports. The existence of such a cell type contradicts current theory on how organs arise from cell layers in the embryo, and may hold clues to origins of, and future treatment for, liver cancer.
Medications remain the mainstay of epilepsy treatment, and to date there are no FDA-approved devices that provide an accurate means of detection for generalized tonic-clonic seizures, or convulsions, during activities of daily living. Two new studies presented at the American Epilepsy Society's 67th Annual Meeting in Washington D.C. provide data that warrants the development of non-invasive devices with the capability to signal the onset of an epileptic seizure and could be crucial to optimal patient dosing.
› Verified 3 days ago
Dr. Basel Skeif, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5140 E Glenn St, Tucson, AZ 85712 Phone: 520-838-3540 Fax: 520-325-3526 | |
Dr. David Spencer Hamilton Sr., MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3601 S 6th Ave, Tucson, AZ 85723 Phone: 520-792-1450 | |
Diana Silva Cantillo, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1230 S Cherrybell Stra, Tucson, AZ 85713 Phone: 520-628-8287 | |
Basel Shoua, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2070 W Rudasill Rd Ste 130, Tucson, AZ 85704 Phone: 520-797-4468 Fax: 520-797-4502 | |
Hadil Owaynat, DO Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1501 N Campbell Ave Rm 6336, Tucson, AZ 85724 Phone: 520-626-2760 Fax: 520-626-6020 | |
Dr. David M Schwartz, DO Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6200 N La Cholla Blvd, Tucson, AZ 85741 Phone: 520-469-8011 Fax: 520-469-8021 | |
Kenneth Alex Murachanian, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6060 N Fountain Plaza Dr Ste 270, Tucson, AZ 85704 Phone: 520-229-2578 |